Teripressin, the chemical name of which is triglylyl lysine vasopressin, is a new synthetic long-acting vasopressin preparation. It is a precursor drug, itself inactive, in vivo by aminopeptidase Chemicalbook, after removing its N terminal 3 glycinyl residues, slowly "release" of the active lysine vasopressin, so teripressin is equivalent to a stable rate of lysine vasopressin release reservoir. 

Terlivasopressin is a new synthetic long-acting vasopressin preparation, which belongs to a precursor drug, which is inactive in itself. After the action of aminopeptidase, the 3 glycinyl residues at the n-terminal are removed in vivo, and the active lysine vasopressin is slowly "released". It is this "slow release" mechanism that allows it to maintain smooth muscle contraction for up to 10 hours after a single administration, while the same dose of vasopressin can only maintain its activity for 20-40 minutes. On the other hand, due to the slow enzymatic hydrolysis, the circulating lysine vasopressin does not reach the toxic level, so the use of teripressin is relatively safe. The pharmacological effect of terlipressin is to shrink visceral vascular smooth muscle, reduce visceral blood flow (such as reducing the blood flow of mesentery, spleen, uterus, etc.), thus reducing portal blood flow and portal venous pressure. On the other hand, it can also reduce the effect of plasma renin concentration, thereby increasing the renal blood flow in patients with hepatorenal syndrome. Improve kidney function and increase urine output. Terlipressin is currently the only drug that can improve the survival rate of patients with esophageal variceal rupture and hemorrhage. Previously, it was mainly used in clinical treatment of variceal rupture and hemorrhage. In addition, terlipressin has also been successfully used in liver and kidney synthesis, and is likely to play a beneficial role in concurrent refractory shock and cardiopulmonary resuscitation. Compared with vasopressin, it has a long-lasting effect, does not cause dangerous complications, including pro-fibrinolysis and serious complications of the cardiovascular system, and is simple to use (can be injected intravenically), and is more suitable for the rescue and treatment of critically ill patients.